NASDAQ:AUPH Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis $14.70 -0.19 (-1.28%) Closing price 11/20/2026 03:59 PM EasternExtended Trading$14.76 +0.06 (+0.39%) As of 11/20/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AUPH alerts:Sign Up Key Stats Today's Range$14.63▼$14.9750-Day Range$14.70▼$17.3652-Week Range$13.52▼$19.25Volume1.34 million shsAverage Volume942,391 shsMarket Capitalization$1.97 billionP/E Ratio6.42Dividend YieldN/APrice Target$17.33Consensus RatingModerate Buy Company Overview Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company’s work has centered on therapies for conditions that can affect the kidneys and other organs. Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy. Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis. Its activities have included the development and commercialization of Lupkynis, with a focus on serving patients in the United States and other markets where the medicine is authorized.AI Generated. May Contain Errors. Read More Aurinia Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreAUPH MarketRank™: 3.498527968595 of 5 starsAurinia Pharmaceuticals scored higher than 70% of companies evaluated by MarketBeat, and ranked 195th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 2 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialAurinia Pharmaceuticals has a consensus price target of $17.33, representing about 17.9% upside from its current price of $14.70.Amount of Analyst CoverageAurinia Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Aurinia Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth7.22% Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow by 7.22% in the coming year, from $0.97 to $1.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is 6.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.19.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is 6.42, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.56.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.94% of the float of Aurinia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 10.31, which indicates bearish sentiment.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently decreased by 8.26%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.8 / 5News SentimentN/A News SentimentAurinia Pharmaceuticals has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aurinia Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest4 people have searched for AUPH on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows3 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.40% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.Read more about Aurinia Pharmaceuticals' insider trading history. Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AUPH Stock News HeadlinesAurinia Pharmaceuticals (AUPH) AI Stock AnalysisNovember 13, 2026 | tipranks.comAurinia: Paying For Growth That Is Already FadingNovember 10, 2026 | seekingalpha.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 22 at 1:00 AM | Profits Run (Ad)Analysts Are Bullish on These Healthcare Stocks: Aurinia Pharmaceuticals (AUPH), AbbVie (ABBV)November 4, 2026 | theglobeandmail.comRBC Raises Price Target on Aurinia Pharmaceuticals to $18 From $16, Keeps Sector Perform, Speculative RiskNovember 2, 2026 | marketscreener.comMAurinia Pharmaceuticals Inc. Raises Earnings Guidance for the Full Fiscal Year 2026October 30, 2026 | marketscreener.comMAurinia Skids on ResultsOctober 30, 2026 | baystreet.caEarnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q3 Revenue $83.7M, vs. FactSet Est of $83.6MOctober 30, 2026 | marketscreener.comMSee More Headlines AUPH Stock Analysis - Frequently Asked Questions How have AUPH shares performed this year? Aurinia Pharmaceuticals' stock was trading at $15.95 at the beginning of the year. Since then, AUPH stock has decreased by 7.8% and is now trading at $14.6990. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) posted its earnings results on Friday, October, 30th. The biotechnology company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of $0.22 by $0.01. The biotechnology company had revenue of $83.70 million for the quarter, compared to the consensus estimate of $83.61 million. Aurinia Pharmaceuticals had a net margin of 97.68% and a trailing twelve-month return on equity of 22.99%. Who are Aurinia Pharmaceuticals' major shareholders? Aurinia Pharmaceuticals' top institutional investors include Goldman Sachs Group Inc. (4.73%), State Street Corp (1.93%), Marshall Wace LLP (1.42%) and Ritholtz Wealth Management (0.30%). Insiders that own company stock include Kevin Tang, Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Greg Keenan and Jeffrey Allen Bailey. View institutional ownership trends. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Palantir Technologies (PLTR), Tesla (TSLA), Exelixis (EXEL) and Block (XYZ). Company Calendar Last Earnings10/30/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 2 days ago, AUPH's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AUPH CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees128Year Founded2013Price Target and Rating Average Price Target for Aurinia Pharmaceuticals$17.33 High Price Target$18.00 Low Price Target$16.00 Potential Upside/Downside+17.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$2.29 Trailing P/E Ratio6.42 Forward P/E Ratio14.13 P/E GrowthN/ANet Income$287.20 million Net Margins97.68% Pretax Margin51.94% Return on Equity22.99% Return on Assets17.99% Debt Debt-to-Equity Ratio0.06 Current Ratio6.12 Quick Ratio5.67 Sales & Book Value Annual Sales$283.05 million Price / Sales6.96 Cash Flow$1.01 per share Price / Cash Flow14.51 Book Value$4.91 per share Price / Book2.99Miscellaneous Outstanding Shares134,000,000Free Float120,063,000Market Cap$1.97 billion OptionableOptionable Beta1.40 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:AUPH) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredGold Miners Post Record Cash Flows as AI Stocks WobbleGold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredNoah’s Ark found?Scientists may have discovered Noah's Ark buried under a mountain in eastern Turkey, just two miles from the I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.